We found that CYB5A is closely related to tumor development as it is significantly downregulated in prostate cancer, adrenocortical cancer, breast cancer, and HCC [4, 6, 39, 40] and can inhibit the proliferation and metastasis of pancreatic cancer cells [8]. Here, CYB5A is linked to prostate carcinoma.